A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy
- Multiple Myeloma
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Janssen Research & Development, LLC
- Enrolment target
- 1,590
- Started
- 25 October 2022
- Main results due
- 30 April 2031
- Study sites
- 270
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Have a diagnosis of multiple myeloma according to the International Myeloma Working Group (IMWG) diagnostic criteria * Be newly diagnosed and not considered a candidate for high-dose chemotherapy with autologous stem cell transplant (ASCT) due to: ineligible due to advanced age OR; ineligible due to the presence of comorbid condition(s) likely to have a negative impact on tolerability of high-dose chemotherapy with ASCT OR; deferral of high-dose chemotherapy with ASCT as initial treatment * Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2 * A participant must agree not to be pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment * A participant must agree not to plan to father a child while enrolled in this study or within 100 days after the last dose of study treatment Exclusion Criteria: * Received any prior therapy for multiple myeloma or smoldering myeloma other than a short course of corticosteroids (not to exceed total of 160 milligrams \[mg\] dexamethasone or equivalent). In addition, received a cumulative dose of systemic corticosteroids equivalent to greater than or equals to (\>=) 20 mg of dexamethasone within 14 days before randomization * Had plasmapheresis within 28 days of randomization * Had a stroke, transient ischemic attack, or seizure within 6 months prior to randomization * Known allergies, hypersensitivity, or intolerance to teclistamab or talquetamab excipients * Known contraindications to the use of daratumumab or lenalidomide per local prescribing information * Myeloma Frailty Index of \>=2 with the exception of participants who have a score of 2 based on age alone
What this study is about
In the sponsor’s own words, from the registry.
The purpose of this study is to compare the efficacy of teclistamab in combination with daratumumab and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab and lenalidomide (Tal-DR) versus daratumumab, lenalidomide, dexamethasone (DRd).
Study sites(270)
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States
Recruiting
University of Arizona Cancer Center
Tucson, Arizona, United States
Recruiting
UCSF Fresno
Clovis, California, United States
Recruiting
City of Hope Duarte
Duarte, California, United States
Recruiting
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California, United States
Recruiting
Cancer and Blood Specialty Clinic
Los Alamitos, California, United States
Recruiting
Valkyrie Clinical Trials
Los Angeles, California, United States
Recruiting
University of Connecticut
Farmington, Connecticut, United States
Recruiting
Yale New Haven Hospital
New Haven, Connecticut, United States
Recruiting
ChristianaCare Helen F Graham Cancer Center and Research Institute
Newark, Delaware, United States
Recruiting
Memorial Healthcare System
Hollywood, Florida, United States
Recruiting
AdventHealth Medical Group Blood & Marrow Transplant at Orlando
Orlando, Florida, United States
Recruiting
Cleveland Clinic Florida
Weston, Florida, United States
Recruiting
City of Hope Cancer Center
Newnan, Georgia, United States
Recruiting
University Of Illinois Medical Center
Chicago, Illinois, United States
Recruiting
Loyola University Medical Center
Maywood, Illinois, United States
Recruiting
University of Iowa Health Care
Waukee, Iowa, United States
Recruiting
Norton Cancer Institute
Louisville, Kentucky, United States
Recruiting
LSUHSC Shreveport Feist-Weiller Cancer Center
Shreveport, Louisiana, United States
Recruiting
Johns Hopkins University School of Medicine JHUSOM
Baltimore, Maryland, United States
Recruiting
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States
Recruiting
University of Michigan
Ann Arbor, Michigan, United States
Recruiting
Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion
Detroit, Michigan, United States
Recruiting
Cancer And Hematology Centers of Western Michigan PC
Grand Rapids, Michigan, United States
Recruiting
Henry Ford Providence Novi Hospital
Novi, Michigan, United States
Recruiting
Henry Ford Providence Southfield CK Potluri Cancer Center
Southfield, Michigan, United States
Recruiting
MidAmerica Cancer Care
Kansas City, Missouri, United States
Recruiting
Nebraska Cancer Specialists
Omaha, Nebraska, United States
Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, United States
Recruiting
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
Recruiting
Astera Cancer Care
East Brunswick, New Jersey, United States
Recruiting
Christus St. Vincent Regional Cancer Center
Santa Fe, New Mexico, United States
Recruiting
Hematology-Oncology Associates of CNY
East Syracuse, New York, United States
Recruiting
Northwell Health Cancer Institute
Lake Success, New York, United States
Recruiting
NYU Langone Hospital Long Island
Mineola, New York, United States
Recruiting
Perlmutter Cancer Center at NYU Langone Health
New York, New York, United States
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Recruiting
Weill Cornell Medical College
New York, New York, United States
Recruiting
Levine Cancer Institute
Charlotte, North Carolina, United States
Recruiting
Novant Health
Charlotte, North Carolina, United States
Recruiting
Durham VAMC
Durham, North Carolina, United States
Recruiting
Novant Health Zimmer Cancer Institute
Wilmington, North Carolina, United States
Recruiting
Novant Health Forsyth Medical Center
Winston-Salem, North Carolina, United States
Recruiting
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
Recruiting
The Christ Hospital Cancer Center
Cincinnati, Ohio, United States
Recruiting
Oncology Hematology Care
Cincinnati, Ohio, United States
Recruiting
University of Cincinnati
Cincinnati, Ohio, United States
Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Recruiting
Cleveland Clinic Main Campus
Cleveland, Ohio, United States
Recruiting
The Ohio State University- James Cancer Hospital
Columbus, Ohio, United States
Recruiting
OhioHealth
Columbus, Ohio, United States
Recruiting
Penn State Milton S Hershey Medical Ctr
Hershey, Pennsylvania, United States
Recruiting
Allegheny Health Network
Pittsburgh, Pennsylvania, United States
Recruiting
Rhode Island Hospital
Providence, Rhode Island, United States
Recruiting
MUSC-Hollings Cancer Center
Charleston, South Carolina, United States
Recruiting
Henry-Joyce Cancer Clinic
Nashville, Tennessee, United States
Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Recruiting
Houston Methodist Hospital
Houston, Texas, United States
Recruiting
Joe Arrington Cancer Research Treatment Center
Lubbock, Texas, United States
Recruiting
Utah Cancer Specialists
Salt Lake City, Utah, United States
Recruiting
Showing 60 of 270 sites — filter to narrow it down. 69 of the 270 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT05552222. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me